Citation Impact
Citing Papers
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.
1994
ATP-dependent 17β-Estradiol 17-(β-D-Glucuronide) Transport by Multidrug Resistance Protein (MRP)
1996
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)
2001
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
2010
Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
2007
Hepatocellular carcinoma
2003 Standout
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
2008
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Pancreatic cancer
2020 Standout
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
2012
Marine natural products
1990 Standout
Cushing's syndrome
2015 Standout
Cancer Statistics, 2006
2006 Standout
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
2001
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Synthetic approaches to the 2012 new drugs
2014
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s
2007
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors
2016
Classification and functions of enteroendocrine cells of the lower gastrointestinal tract
2011
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
2006
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide
2014
Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial
2008
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
2011
Cushing’s syndrome complicated by multiple opportunistic infections
1998
Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.
1989
Management of Hepatocellular Carcinoma *
2005 Standout
Clinical applications of newer radionuclide therapies
2006
Targeting multidrug resistance in cancer
2006 Standout
Carcinoid A Comprehensive Review
2003
The golden age: gold nanoparticles for biomedicine
2011 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma
2002
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
2009 Standout
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
A 5‐decade analysis of 13,715 carcinoid tumors
2003 Standout
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors
2005
Use of the Somatostatin Analogue Octreotide Acetate in the Treatment of Encephalopathy Associated with Carcinoid Tumor
1997
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
2008
Pharmacological Importance of Stereochemical Resolution of Enantiomeric Drugs
1997
Update on the treatment of neuroendocrine tumors
2003
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#
2007
Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis
2015 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Interventional treatment of neuroendocrine liver metastases
2008
Treatment of Type II Gastric Carcinoid Tumors with Somatostatin Analogues
2000
Pasireotide (SOM230): Development, mechanism of action and potential applications
2007
A review on emerging contaminants in wastewaters and the environment: Current knowledge, understudied areas and recommendations for future monitoring
2014 Standout
Regression of a Large Malignant Gastrinoma on Treatment with Sandostatin LAR®: A Case Report
2008
Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting
1990
Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors
2003
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
2004
Measuring the Relationship of Quality of Life and Health Status, Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors
2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
2010
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Evaluation of a Maleimido Derivative of CHX-A′′ DTPA for Site-Specific Labeling of Affibody Molecules
2008
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump)
1998 StandoutNobel
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
The Current State of Peptide Drug Discovery: Back to the Future?
2017
Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
2003
Review: The Management of Nausea and Vomiting in Clinical Oncology
1987
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Prognosis of Carcinoid Heart Disease
2005
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy
2004
Neuroendocrine Tumor‐Targeted Upconversion Nanoparticle‐Based Micelles for Simultaneous NIR‐Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging
2017
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
2005
Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
2002
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
2011
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
2006
Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?
2011
Opportunistic Infections in Endogenous Cushing's Syndrome
1984
Iron-Deficiency Anemia
2015 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Light-Controlled Radical Polymerization: Mechanisms, Methods, and Applications
2016 Standout
Carcinoid Tumors of the Gut
1997
Dynamic Inversion of Stereoselective Phosphate Binding to a Bisurea Receptor Controlled by Light and Heat
2015 StandoutNobel
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
2016 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
2000
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
2018 Standout
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
1992
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology
2002
Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer
2019
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Axinellins A and B: New Proline-Containing Antiproliferative Cyclopeptides from the Vanuatu SpongeAxinella carteri
1998
Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
2001
Works of Lowell Anthony being referenced
NANETS Treatment Guidelines
2010
Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period
2011
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
2002
Quinidine reduces clearance of (+)-propranolol more than (−)-propranolol through marked reduction in 4-hydroxylation
1990
Somatostatin Receptor Imaging: Predictive and Prognostic Considerations
1996
Somatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms
1993
Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors
1998
Surgical Treatment of Advanced-Stage Carcinoid Tumors
2005
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
2012
Consensus statement: Octreotide dose titration in secretory diarrhea
1995
The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs)
2010
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
1998
Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.
1986
Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
1999
Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit.
1988
Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).
2011
Safety Profile of Iron Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia.
2006
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
2010
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
2005
From somatostatin to octreotide LAR: evolution of a somatostatin analogue
2009
Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis
2016
In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
2000
High-Dose Indium 111In Pentetreotide Radiotherapy for Metastatic Atypical Carcinoid Tumor*
2000
Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study
2006
Pneumocystis carinii Pneumonia: A Complication of Cushing's Syndrome
1981
A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy
2007